{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-103727","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2024-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.314042+00:00","generated_at":"2026-05-31T06:19:28.695316+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"low","headline":"enGene Holdings updates corporate presentation; no specific operational or financial changes disclosed","bullets":["Corporate presentation dated September 5, 2024 furnished as Exhibit 99.1.","Presentation titled 'Non-Viral Genetic Medicine' — no new pipeline or financial data provided in this filing.","No material events such as earnings, leadership changes, or financing announced."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-103727","json":"https://secwatch.observer/filing/0000950170-24-103727.json","markdown":"https://secwatch.observer/filing/0000950170-24-103727.md","text":"https://secwatch.observer/filing/0000950170-24-103727.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024103727/0000950170-24-103727-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000095017024103727/engn-20240905.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:19:28.695316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}